Journal Papers,
Abstracts, and Commentaries
| |
Development of resistance mutations in women receiving standard
antiretroviral therapy
who received intrapartum nevirapine to prevent perinatal human
immunodeficiency virus
type
1
transmission: a substudy of pediatric AIDS clinical trials group
protocol 316.
Cunningham CK,
Chaix ML, Rekacewicz C, et al
J Infect Dis 2002 Jul 15;186(2):181-8
Abstract
Identification of the K103N resistance mutation in Ugandan women
receiving nevirapine to
prevent HIV-1 vertical transmission.
Jackson JB, Becker-Pergola G, Guay LA, et
al
AIDS 2000 Jul
28;14(11):F111-5
Abstract
Pharmacological
implications of lengthened in-utero exposure to nevirapine.
Taylor GP, Lyall EG, Back D, Ward C,
Tudor-Williams G.
Lancet 2000
Jun 17;355(9221):2134-5
Abstract
|
|
Conference
Reports, Abstracts, and Posters
| |
Low emergence of nevirapine (NVP) and lamivudine (3TC) resistance
after post-partum
interruption of a triple drug regimen for prevention of HIV mother
to child transmission
(MTCT)
Pérez H, Vignoles M, Laufer N, et al
(4th IAS Conference)
Abstract
|
Development of phenotypic HIV-1 drug resistance following exposure
to single dose nevirapine
Basson A, Ntsala M, Tlale E, et al
(4th IAS
Conference)
Abstract
|
Detection of the onset of drug resistant mutations in pregnant women
receiving single dose
nevirapine in Namakkal, Tamilnadu, using oligonucleotide ligation
assay
Jacob SM, Durairaj A, Vijayakumari JJ, et al
(4th
IAS Conference)
Abstract
|
Clonal analysis of the diversity in drug resistant subtype C HIV-1
after single dose nevirapine
Kassaye S., Lee E., Johnston B., Kantor R., Katzenstein D.
(XVI
International AIDS Conference)
Abstract
|
Resistance induced by the use of single dose nevirapine (sdNVP) for
prevention of
mother-to-child
transmission of HIV (PMTCT): debate and reality, experience in
Nigeria
Mandala J., Abutu A., Anomnachi L
(XVI
International AIDS Conference)
Abstract
|
POSTER
Analysis
of K103N-containing HIV-1 Variants in Women with HIV-1 Subtypes A,
C, and D
after Single-dose Nevirapine Using a Sensitive and Quantitative
Point Mutation Assay
T
S. Flys, S Chen, D Jones, et al
(13 CROI)
PDF
Poster
Abstract
|
Selection of Resistance Mutations in Children Receiving Prophylaxis
with Lamivudine or
Nevirapine for the Prevention of Postnatal Transmission of HIV
M Giuliano, C Galluzzo, E Germinario, et al
(12 CROI)
Abstract
|
Clonal Analysis of Drug-resistant Mutations in Plasma
and Breast Milk following
Single-dose Nevirapine
E
Lee, R Kantor, E Johnston, et al
(12 CROI)
Abstract
|
Controversies in the Use of Nevirapine for Prevention
of Mother-to-Child Transmission
J McIntyre
(12 CROI)
Abstract
|
Infant Zidovudine Prophylaxis and Emergence of Nevirapine Resistance
at 6 Weeks in
Perinatally HIV-infected Infants Exposed to Intra-partum or Newborn
Nevirapine
N
Ngo-Giang-Huong, G Jourdain, P Tungyai, et al
(12 CROI)
Abstract
|
Sensitive Drug Resistance Assays Reveal Long-term Persistence of
HIV-1 Variants with
the K103N Nevirapine-resistance Mutation in Some Women and Infants
after Single-dose
NVP: HIVNET 012
S
Eshleman, D Nissley, C Claasen, et al
(12 CROI)
Abstract
|
Nevirapine Resistance and Survival of Women Receiving HAART
Subsequent to Prevention
of Mother-to-Child Transmission: A Population-based Stochastic
Model
D Westreich , A Van Rie, F Behets, et
al
(12 CROI)
Abstract
|
Persistence of NNRTI-r Resistant Variants after Single-dose
Nevirapine in HIV-1 Subtype-
C-infected Women
S
Palmer , V Boltz , F Maldarelli, et al
(12 CROI)
Abstract
|
Resistance Emerges in the Majority of Women
Provided Intrapartum Single-dose Nevirapine
J Johnson, J F Li, L Morris, et al
(12 CROI)
Abstract
Nevirapine resistance mutations among HIV-1 infected infants
following single dose nevirapine
CCN Pillay, G Gray, C Chezzi, et al
(15IAC)
Abstract
Resistance patterns in mother-infant pairs following
single dose nevirapine (NVP) for the
prevention of mother-to-child transmission (MTCT) of
HIV-1.
M Gordon, N Graham, R Bland, et al
(15IAC)
Abstract
|
Comparison of genotypic and phenotypic assays for
measuring nevirapine resistance
among women
participating in mother-to-child prevention programs
M Ntsala, C Pillay, E Tlale, et al
(15IAC)
Abstract
Persistence of nevirapine resistance mutations 6
months following single dose nevirapine
L Morris, N Martinson, C Pillay,et al
(15IAC)
Abstract
|
Profile of NNRI associated mutations in women
exposed to a single dose of nevirapine
during delivery in Thailand
N Ngo-Giang-Huong, P Tungyai, A Kummee
(15IAC)
Abstract |
Modeling the sexual transmission of HIV-1 strains
resistant to nevirapine from MTCT programs
A Medley, K O’Reilly, G Schmid, M D Sweat
(15IAC)
Abstract
HIV-1 GENOTYPIC RESISTANCE TO ANTIRETROVIRAL
TREATMENT IN CAMEROON,
IN POPULATIONS TREATED BY HAART AND BY SINGLE-DOSE
NEVIRAPINE TO
PREVENT MTCT
C. Kouanfack, L. Vergne, M. Tardy, et al
(2nd
IAS)
Abstract
|
|
|
|
|
|
POSTER
Nevirapine Plasma
Concentrations Are Still Detectable after More than 2 Weeks in the
Majority of Women Receiving Single-dose NVP: Implications for
Intervention Studies
E Muro, J Droste, H ter Hofstede,
et al
(11
CROI
 PDF
Poster
Abstract
|
Selection of Nevirapine Resistance (NVPR) Mutations in Ugandan Women and
Infants
Receiving NVP Prophylaxis To Prevent HIV-1 Vertical Transmission
(HIVNET-012).
(8 CROI)
Abstract |
|
Journal Papers, Abstracts,
and Commentaries
| |
FULL-TEXT ARTICLE
Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to
Nevirapine-
Based Antiretroviral Therapy.
Jourdain G, Ngo-Giang-Huong N,
Le Coeur S, et al
N Engl J Med. 2004 Jul 9
Abstract
|
|
|
Perinatal
NVP Main Page
